Kradin R L, Boyle L A, Preffer F I, Callahan R J, Barlai-Kovach M, Strauss H W, Dubinett S, Kurnick J T
Cancer Immunol Immunother. 1987;24(1):76-85. doi: 10.1007/BF00199837.
A trial of adoptive immunotherapy was performed in which long-term cultured, interleukin-2 (IL2)-dependent T-lymphocytes were administered to patients with metastatic adenocarcinoma of the lung. Lymphocytes were isolated from explants of cancer tissues that were cultured in medium with recombinant IL-2. These T-cells expressed surface markers of activation, and killed a broad panel of tumor targets. Intravenously injected 111indium-labeled T-cell blasts distributed primarily to lungs, liver, and spleen. Despite a paucity of infused lymphocytes detected by external imaging at sites of tumor, five of seven patients showed reduction of their cancers. However, in no case was greater than 50% reduction of total tumor burden achieved. Evidence of increased delayed cutaneous hypersensitivity to protein antigens was observed in three patients following therapy. We conclude that long-term cultured tumor-derived T-cells can be transferred safely into humans and that these cells may be capable of enhancing immune responses and mediating tumor reduction in vivo.
进行了一项过继性免疫疗法试验，将长期培养的、依赖白细胞介素-2（IL2）的T淋巴细胞给予肺转移性腺癌患者。淋巴细胞从在含重组IL-2的培养基中培养的癌组织外植体中分离出来。这些T细胞表达活化的表面标志物，并能杀伤多种肿瘤靶标。静脉注射的铟-111标记的T细胞母细胞主要分布于肺、肝和脾。尽管通过外部成像在肿瘤部位检测到注入的淋巴细胞很少，但7名患者中有5名患者的癌症出现缓解。然而，在任何情况下，肿瘤总负担的减轻均未超过50%。治疗后，3名患者出现对蛋白质抗原的迟发型皮肤超敏反应增强的证据。我们得出结论，长期培养的肿瘤来源的T细胞可以安全地转移到人体内，并且这些细胞可能能够增强免疫反应并在体内介导肿瘤缩小。
